No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
View/ Open
Date
2016-05-01Author
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2,
Hollestelle, A
van der Baan, FH
Berchuck, A
Johnatty, SE
Aben, KK
Agnarsson, BA
Aittomäki, K
Alducci, E
Andrulis, IL
Anton-Culver, H
Antonenkova, NN
Antoniou, AC
Apicella, C
Arndt, V
Arnold, N
Arun, BK
Arver, B
Ashworth, A
Australian Ovarian Cancer Study Group,
Baglietto, L
Balleine, R
Bandera, EV
Barrowdale, D
Bean, YT
Beckmann, L
Beckmann, MW
Benitez, J
Berger, A
Berger, R
Beuselinck, B
Bisogna, M
Bjorge, L
Blomqvist, C
Bogdanova, NV
Bojesen, A
Bojesen, SE
Bolla, MK
Bonanni, B
Brand, JS
Brauch, H
Breast Cancer Family Register,
Brenner, H
Brinton, L
Brooks-Wilson, A
Bruinsma, F
Brunet, J
Brüning, T
Budzilowska, A
Bunker, CH
Burwinkel, B
Butzow, R
Buys, SS
Caligo, MA
Campbell, I
Carter, J
Chang-Claude, J
Chanock, SJ
Claes, KBM
Collée, JM
Cook, LS
Couch, FJ
Cox, A
Cramer, D
Cross, SS
Cunningham, JM
Cybulski, C
Czene, K
Damiola, F
Dansonka-Mieszkowska, A
Darabi, H
de la Hoya, M
deFazio, A
Dennis, J
Devilee, P
Dicks, EM
Diez, O
Doherty, JA
Domchek, SM
Dorfling, CM
Dörk, T
Silva, IDS
du Bois, A
Dumont, M
Dunning, AM
Duran, M
Easton, DF
Eccles, D
Edwards, RP
Ehrencrona, H
Ejlertsen, B
Ekici, AB
Ellis, SD
EMBRACE,
Engel, C
Eriksson, M
Fasching, PA
Feliubadalo, L
Figueroa, J
Flesch-Janys, D
Fletcher, O
Fontaine, A
Fortuzzi, S
Fostira, F
Fridley, BL
Friebel, T
Friedman, E
Friel, G
Frost, D
Garber, J
García-Closas, M
Gayther, SA
GEMO Study Collaborators,
GENICA Network,
Gentry-Maharaj, A
Gerdes, A-M
Giles, GG
Glasspool, R
Glendon, G
Godwin, AK
Goodman, MT
Gore, M
Greene, MH
Grip, M
Gronwald, J
Gschwantler Kaulich, D
Guénel, P
Guzman, SR
Haeberle, L
Haiman, CA
Hall, P
Halverson, SL
Hamann, U
Hansen, TVO
Harter, P
Hartikainen, JM
Healey, S
HEBON,
Hein, A
Heitz, F
Henderson, BE
Herzog, J
T Hildebrandt, MA
Høgdall, CK
Høgdall, E
Hogervorst, FBL
Hopper, JL
Humphreys, K
Huzarski, T
Imyanitov, EN
Isaacs, C
Jakubowska, A
Janavicius, R
Jaworska, K
Jensen, A
Jensen, UB
Johnson, N
Jukkola-Vuorinen, A
Kabisch, M
Karlan, BY
Kataja, V
Kauff, N
KConFab Investigators,
Kelemen, LE
Kerin, MJ
Kiemeney, LA
Kjaer, SK
Knight, JA
Knol-Bout, JP
Konstantopoulou, I
Kosma, V-M
Krakstad, C
Kristensen, V
Kuchenbaecker, KB
Kupryjanczyk, J
Laitman, Y
Lambrechts, D
Lambrechts, S
Larson, MC
Lasa, A
Laurent-Puig, P
Lazaro, C
Le, ND
Le Marchand, L
Leminen, A
Lester, J
Levine, DA
Li, J
Liang, D
Lindblom, A
Lindor, N
Lissowska, J
Long, J
Lu, KH
Lubinski, J
Lundvall, L
Lurie, G
Mai, PL
Mannermaa, A
Margolin, S
Mariette, F
Marme, F
Martens, JWM
Massuger, LFAG
Maugard, C
Mazoyer, S
McGuffog, L
McGuire, V
McLean, C
McNeish, I
Meindl, A
Menegaux, F
Menéndez, P
Menkiszak, J
Menon, U
Mensenkamp, AR
Miller, N
Milne, RL
Modugno, F
Montagna, M
Moysich, KB
Müller, H
Mulligan, AM
Muranen, TA
Narod, SA
Nathanson, KL
Ness, RB
Neuhausen, SL
Nevanlinna, H
Neven, P
Nielsen, FC
Nielsen, SF
Nordestgaard, BG
Nussbaum, RL
Odunsi, K
Offit, K
Olah, E
Olopade, OI
Olson, JE
Olson, SH
Oosterwijk, JC
Orlow, I
Orr, N
Orsulic, S
Osorio, A
Ottini, L
Paul, J
Pearce, CL
Pedersen, IS
Peissel, B
Pejovic, T
Pelttari, LM
Perkins, J
Permuth-Wey, J
Peterlongo, P
Peto, J
Phelan, CM
Phillips, K-A
Piedmonte, M
Pike, MC
Platte, R
Plisiecka-Halasa, J
Poole, EM
Poppe, B
Pylkäs, K
Radice, P
Ramus, SJ
Rebbeck, TR
Reed, MWR
Rennert, G
Risch, HA
Robson, M
Rodriguez, GC
Romero, A
Rossing, MA
Rothstein, JH
Rudolph, A
Runnebaum, I
Salani, R
Salvesen, HB
Sawyer, EJ
Schildkraut, JM
Schmidt, MK
Schmutzler, RK
Schneeweiss, A
Schoemaker, MJ
Schrauder, MG
Schumacher, F
Schwaab, I
Scuvera, G
Sellers, TA
Severi, G
Seynaeve, CM
Shah, M
Shrubsole, M
Siddiqui, N
Sieh, W
Simard, J
Singer, CF
Sinilnikova, OM
Smeets, D
Sohn, C
Soller, M
Song, H
Soucy, P
Southey, MC
Stegmaier, C
Stoppa-Lyonnet, D
Sucheston, L
SWE-BRCA,
Swerdlow, A
Tangen, IL
Tea, M-K
Teixeira, MR
Terry, KL
Terry, MB
Thomassen, M
Thompson, PJ
Tihomirova, L
Tischkowitz, M
Toland, AE
Tollenaar, RAEM
Tomlinson, I
Torres, D
Truong, T
Tsimiklis, H
Tung, N
Tworoger, SS
Tyrer, JP
Vachon, CM
Van 't Veer, LJ
van Altena, AM
Van Asperen, CJ
van den Berg, D
van den Ouweland, AMW
van Doorn, HC
Van Nieuwenhuysen, E
van Rensburg, EJ
Vergote, I
Verhoef, S
Vierkant, RA
Vijai, J
Vitonis, AF
von Wachenfeldt, A
Walsh, C
Wang, Q
Wang-Gohrke, S
Wappenschmidt, B
Weischer, M
Weitzel, JN
Weltens, C
Wentzensen, N
Whittemore, AS
Wilkens, LR
Winqvist, R
Wu, AH
Wu, X
Yang, HP
Zaffaroni, D
Pilar Zamora, M
Zheng, W
Ziogas, A
Chenevix-Trench, G
Pharoah, PDP
Rookus, MA
Hooning, MJ
Goode, EL
Type
Journal Article
Metadata
Show full item recordAbstract
OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with survival time. However, prior studies, emphasizing particular subgroups, were relatively small. Therefore, we comprehensively evaluated ovarian and breast cancer risks as well as clinical outcome associated with rs61764370. METHODS: Centralized genotyping and analysis were performed for 140,012 women enrolled in the Ovarian Cancer Association Consortium (15,357 ovarian cancer patients; 30,816 controls), the Breast Cancer Association Consortium (33,530 breast cancer patients; 37,640 controls), and the Consortium of Modifiers of BRCA1 and BRCA2 (14,765 BRCA1 and 7904 BRCA2 mutation carriers). RESULTS: We found no association with risk of ovarian cancer (OR=0.99, 95% CI 0.94-1.04, p=0.74) or breast cancer (OR=0.98, 95% CI 0.94-1.01, p=0.19) and results were consistent among mutation carriers (BRCA1, ovarian cancer HR=1.09, 95% CI 0.97-1.23, p=0.14, breast cancer HR=1.04, 95% CI 0.97-1.12, p=0.27; BRCA2, ovarian cancer HR=0.89, 95% CI 0.71-1.13, p=0.34, breast cancer HR=1.06, 95% CI 0.94-1.19, p=0.35). Null results were also obtained for associations with overall survival following ovarian cancer (HR=0.94, 95% CI 0.83-1.07, p=0.38), breast cancer (HR=0.96, 95% CI 0.87-1.06, p=0.38), and all other previously-reported associations. CONCLUSIONS: rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers. Therefore, genotyping this variant has no clinical utility related to the prediction or management of these cancers.
Subject
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2
Australian Ovarian Cancer Study Group
Breast Cancer Family Register
EMBRACE
GEMO Study Collaborators
GENICA Network
HEBON
KConFab Investigators
SWE-BRCA
Humans
Neoplasms, Glandular and Epithelial
Breast Neoplasms
Ovarian Neoplasms
Female
Proto-Oncogene Proteins p21(ras)
Carcinoma, Ovarian Epithelial
Research team
Complex Trait Genetics
Functional Genetic Epidemiology
Medicine (Brown Epigenetic Therapy)
Molecular Epidemiology
Aetiological Epidemiology
Language
eng
Date accepted
2015-04-19
License start date
2016-05
Citation
Gynecologic oncology, 2016, 141 (2), pp. 386 - 401
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Related items
Showing items related by title, author, creator and subject.
-
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
Fehringer, G; Kraft, P; Pharoah, PD; Eeles, RA; Chatterjee, N; et al. (AMER ASSOC CANCER RESEARCH, 2016-09-01)Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, ... -
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals.
Chen, H; Majumdar, A; Wang, L; Kar, S; Brown, KM; et al. (ELSEVIER, 2021-07-08)Genome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic basis can increase our ... -
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers.
Zhang, YD; Hurson, AN; Zhang, H; Choudhury, PP; Easton, DF; et al. (NATURE PORTFOLIO, 2020-07-03)Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of ...